loading page

Response to Pegylated Interferon in a COVID-19 Positive Elderly Woman with Primary Myelofibrosis Treated with Ruxolitinib
  • +7
  • Arthur Frankel,
  • Renuka Reddy,
  • Kayla Desuza,
  • Aaron Carlin,
  • Davey Smith,
  • khaled deeb,
  • Yushuang Xie,
  • Eknath Naik,
  • Richard Silver,
  • Hans Hasselbalch
Arthur Frankel
West Palm Beach VA Medical Center
Author Profile
Renuka Reddy
West Palm Beach VA Medical Center
Author Profile
Kayla Desuza
West Palm Beach VA Medical Center
Author Profile
Aaron Carlin
UCSD
Author Profile
Davey Smith
UCSD
Author Profile
khaled deeb
VA Medical Center
Author Profile
Yushuang Xie
West Palm Beach VA Medical Center
Author Profile
Eknath Naik
West Palm Beach VA Medical Center
Author Profile
Richard Silver
Weill Cornell Medicine
Author Profile
Hans Hasselbalch
Zealand University Hospital Roskilde
Author Profile

Abstract

An 83 year old female had asymptomatic SARS-CoV-2 infection while taking ruxolitinib. She remained RT-PCR positive for viral RNA for >120 days, Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID-19.

Peer review status:ACCEPTED

15 Jan 2021Submitted to Clinical Case Reports
16 Jan 2021Submission Checks Completed
16 Jan 2021Assigned to Editor
22 Jan 2021Reviewer(s) Assigned
23 Jan 2021Review(s) Completed, Editorial Evaluation Pending
24 Jan 2021Editorial Decision: Revise Minor
27 Jan 20211st Revision Received
29 Jan 2021Submission Checks Completed
29 Jan 2021Assigned to Editor
29 Jan 2021Review(s) Completed, Editorial Evaluation Pending
07 Feb 2021Editorial Decision: Accept